From bold reform to abandoned project
Once touted as a bold fix for US pharmaceutical regulation, the voucher program has been left adrift. According to Reuters, its fate reflects the internal chaos, infighting and lack of steady leadership at the FDA, which has had no commissioner since May. For several drugs, the program sped approval by eight months or more, and five of the 12 approvals came after Makary's departure.
One source said FDA leadership told companies the agency was not moving forward with the program, though applications remained open; they are submitted but do not advance. Rich Danker, a former HHS assistant secretary, said the initiative was quietly being phased out following the departure of its top administrator. HHS spokesperson Emily Hilliard, by contrast, said the pilot was ongoing and that the FDA was reviewing feedback from a June public hearing to refine the framework.
“The worst of both worlds”
The program drew fierce criticism from regulatory experts over the handpicking of drugs and the makeup of its executive council, which included former acting drug center director Tracy Beth Hoeg and former biologics chief Vinay Prasad, both of whom left the FDA earlier this year.
“The worst of both worlds.” — Holly Fernandez Lynch















